Intercept to Present at Upcoming Conference

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating in the following investor conference:

• Needham Healthcare Conference at 12:45 p.m. ET on Wednesday, March 28, 2018

Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

CONTACT: For more information aboutIntercept Pharmaceuticals, please contact:    

Intercept Pharmaceuticals:Mark Vignola+1-646-747-1000[email protected]   

Media inquiries: [email protected]   

Investor inquiries: [email protected]

Source: Intercept Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• MoneySimpler Expands AI Quantitative Investment Platform to Support Long-Term Financial Planning
• Eve Air Mobility and Moov Sign LOI for up to 30 eVTOLs to Explore Tourism and Regional Mobility in Cabo Verde
• ANAC Publishes Proposed Noise Certification Criteria for Eve 100